ALLK News and Press, Allakos Inc. From 12/07/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Allakos (NASDAQ: ALLK ): Q3 GAAP EPS of -$0.47 misses by $0.05 . More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ende...

REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced upcoming presentations at the American College of Gastroenterology 2019 Annual S...

Any analyst worth their salt will warn investors that nothing changes quickly in healthcare. Of course, the old axiom doesn't apply to the prices investors will pay for promising new healthcare stocks.  These three healthcare stocks made their first appearance on the  Nasdaq exchan...

Shares of clinical-stage biotech company  Allakos (NASDAQ: ALLK)  soared 154% in August, according to data from  S&P Global Market Intelligence . For context, the S&P 500, including dividends, fell 1.6% last month. In 2019, shares are up 63.6% through Sept...

Allakos ( ALLK ) recently went up 77% in a single trading day after declaring strong positive results from a phase 2 trial. The stock tripled in a matter of days. Then, it launched what Seeking Alpha refers to as an “upsized offering” of $350 million. Normally, even buoyant sto...

Allakos (NASDAQ: ALLK ) upsized its public offering from $200M to $350M and has priced 4,545,454 common shares at $77. More news on: Allakos Inc., Healthcare stocks news, Read more ...

REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the upsizing and pricing of its previously announced un...

Gainers:  EverQuote (NASDAQ: EVER ) +47% . NeoPhotonics Corporation (NYSE: NPTN ) +27% . Invacare Corporation (NYSE: IVC ) +23% . Adient plc (NYSE: ADNT ) +23% . Ducommun Incorporated (NYSE: DCO ) +22% . Insulet Corporation (NASDAQ: PODD ) +19% . Greenlight Capital Re (NASDAQ: G...